Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis
Introduction Metabolic dysfunction-associated steatohepatitis (MASH) is highly prevalent in type 2 diabetes (T2D). Pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RA) are medications used in T2D that can resolve MASH and should be considered in all patients with T2D and MASH. We ass...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2023-11-01
|
| シリーズ: | BMJ Open Diabetes Research & Care |
| オンライン･アクセス: | https://drc.bmj.com/content/11/6/e003763.full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|